|Other Names||Multiple epidermal growth factor-like domains protein 9, Multiple EGF-like domains protein 9, Epidermal growth factor-like protein 5, EGF-like protein 5, MEGF9, EGFL5, KIAA0818|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13358b was selected from the C-term region of MEGF9. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
MEGF9 (multiple EGF-like-domains 9) is a novel transmembrane protein with multiple EGF-like repeats, which is predominantly expressed in the developing and adult CNS (central nervous system) and PNS (peripheral nervous system). The domain structure of MEGF9 consists of an N-terminal region with several potential O-glycosylation sites followed by five EGF-like domains, which are highly homologous with the short arms of laminins. Following one single pass transmembrane domain, a highly conserved short intracellular domain with potential phosphorylation sites is present.
Barber, M.J., et al. PLoS ONE 5 (3), E9763 (2010) :Clark, H.F., et al. Genome Res. 13(10):2265-2270(2003)Nakayama, M., et al. Genomics 51(1):27-34(1998)
If you have any additional inquiries please email technical services at email@example.com.